GNLX:NASDAQ
Genelux Corp
$2.99
arrow_upward
+3.10%(+0.090) 1D
Jul 2, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$2.90
High
$3.04
Low
$2.87
Mkt. cap
134.07M
Avg. vol.
174.92K
Volume
195.98K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.85
Beta
0.58
Shares outstanding
44.84M
No. of employees
26
Open
$2.90
High
$3.04
Low
$2.87
Mkt. cap
134.07M
Avg. vol.
174.92K
Volume
195.98K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.85
Beta
0.58
Shares outstanding
44.84M
No. of employees
26
News stories
From sources across the web
Stock Titan
·
2 days ago
[144] GENELUX Corp SEC Filing
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com
AI content may include mistakes. Learn more